Valeant Pharma (VRX) Reports Q3 EPS of $1.15; Narrows Q4, FY12 EPS Outlook

November 2, 2012 6:03 AM

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q3 EPS of $1.15, versus $0.66 reported last year ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found